share_log

Recursion Pharmaceuticals | 8-K: Current report

Recursion Pharmaceuticals | 8-K: Current report

Recursion Pharmaceuticals | 8-K：重大事件
美股sec公告 ·  06/27 08:17
Moomoo AI 已提取核心信息
On June 26, 2024, Recursion Pharmaceuticals, Inc., a clinical stage TechBio company, announced a public offering of 30,769,230 shares of its Class A common stock at $6.50 per share. The offering, which is expected to close on June 28, 2024, subject to customary closing conditions, could raise approximately $200 million, or up to $230 million if the underwriters exercise their option to purchase additional shares. Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are acting as the representatives of the underwriters for this offering. The company has also entered into lock-up agreements with its executive officers, directors, and certain related entities, restricting the sale of securities for a 45-day period. The offering is made under Recursion's effective registration statement on Form S-3 and related prospectus filed with the SEC. The company aims to use the proceeds for development activities and other corporate purposes, leveraging its Recursion Operating System to industrialize drug discovery.
On June 26, 2024, Recursion Pharmaceuticals, Inc., a clinical stage TechBio company, announced a public offering of 30,769,230 shares of its Class A common stock at $6.50 per share. The offering, which is expected to close on June 28, 2024, subject to customary closing conditions, could raise approximately $200 million, or up to $230 million if the underwriters exercise their option to purchase additional shares. Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are acting as the representatives of the underwriters for this offering. The company has also entered into lock-up agreements with its executive officers, directors, and certain related entities, restricting the sale of securities for a 45-day period. The offering is made under Recursion's effective registration statement on Form S-3 and related prospectus filed with the SEC. The company aims to use the proceeds for development activities and other corporate purposes, leveraging its Recursion Operating System to industrialize drug discovery.
2024年6月26日，临床阶段的TechBio公司Recursion Pharmaceuticals, Inc.宣布以每股6.5美元的价格公开发行30,769,230股A类普通股。预计发行将于2024年6月28日结束，视常规结算条件而定，募集资金可达2亿美元，如果承销商行使购买额外股票的权利则可达2.3亿美元。高盛和摩根大通证券LLC担任此次发行的承销商代表。公司还与其高级管理人员、董事和某些相关实体签署了限制销售证券的锁定协议，为期45天。此次发行是在Recursion的有效S-3表格和提交给证券交易委员会的相关招股书下进行的。公司旨在利用其Recursion操作系统推动药物发现的产业化以及其他企业目的。
2024年6月26日，临床阶段的TechBio公司Recursion Pharmaceuticals, Inc.宣布以每股6.5美元的价格公开发行30,769,230股A类普通股。预计发行将于2024年6月28日结束，视常规结算条件而定，募集资金可达2亿美元，如果承销商行使购买额外股票的权利则可达2.3亿美元。高盛和摩根大通证券LLC担任此次发行的承销商代表。公司还与其高级管理人员、董事和某些相关实体签署了限制销售证券的锁定协议，为期45天。此次发行是在Recursion的有效S-3表格和提交给证券交易委员会的相关招股书下进行的。公司旨在利用其Recursion操作系统推动药物发现的产业化以及其他企业目的。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息